Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 4.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 315,543 shares of the medical research company's stock after purchasing an additional 12,815 shares during the period. Victory Capital Management Inc. owned 0.26% of Natera worth $40,058,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of NTRA. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Natera by 29.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 671,382 shares of the medical research company's stock worth $85,232,000 after purchasing an additional 153,441 shares during the last quarter. Entropy Technologies LP lifted its position in shares of Natera by 35.9% during the third quarter. Entropy Technologies LP now owns 13,634 shares of the medical research company's stock valued at $1,731,000 after buying an additional 3,600 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in shares of Natera in the 3rd quarter valued at about $270,000. Jag Capital Management LLC grew its position in shares of Natera by 8.8% in the 3rd quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company's stock worth $22,291,000 after buying an additional 14,159 shares during the last quarter. Finally, GDS Wealth Management bought a new position in shares of Natera during the 3rd quarter worth approximately $459,000. Institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Leerink Partners upped their price target on Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Sanford C. Bernstein upped their target price on Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Craig Hallum raised their price target on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday. JPMorgan Chase & Co. upped their target price on Natera from $135.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Robert W. Baird increased their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Wednesday. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and an average target price of $137.65.

Insider Activity

In related news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the transaction, the director now owns 7,969 shares in the company, valued at approximately $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the transaction, the chief executive officer now directly owns 195,686 shares of the company's stock, valued at $25,141,737.28. This represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,821 shares of company stock valued at $4,776,878. 7.60% of the stock is currently owned by company insiders.

Natera Price Performance

NTRA traded down $5.05 on Friday, hitting $146.06. 2,242,843 shares of the company's stock were exchanged, compared to its average volume of 1,338,689. Natera, Inc. has a fifty-two week low of $52.01 and a fifty-two week high of $167.79. The stock has a market cap of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. The company has a current ratio of 4.39, a quick ratio of 4.01 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $127.38 and a 200-day moving average price of $115.61.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same period in the prior year, the business earned ($0.95) EPS. The firm's quarterly revenue was up 63.9% on a year-over-year basis. As a group, equities analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.